Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 25,204 | 21,848 | 18,781 | 23,530 | 20,852 |
| Cost of Goods | 2,453 | 2,229 | 1,728 | 2,286 | 2,367 |
| Gross Profit | 22,751 | 19,619 | 17,053 | 21,244 | 18,485 |
| Operating Expenses | 40,749 | 45,687 | 43,521 | 36,139 | 32,352 |
| Operating Income | -17,545 | -25,839 | -25,740 | -14,609 | -13,500 |
| Interest Expense | 2,721 | 3,461 | 2,447 | 3,586 | 3,815 |
| Other Income | -3,316 | -4,065 | -4,045 | -3,967 | -4,573 |
| Pre-tax Income | -23,582 | -33,365 | -32,232 | -22,162 | -21,888 |
| Income Tax | 91 | 38 | 54 | 3,854 | -9 |
| Net Income Continuous | -23,673 | -33,403 | -32,286 | -26,016 | -21,879 |
| Net Income | $-23,673 | $-33,403 | $-32,286 | $-26,016 | $-21,879 |
| EPS Basic Total Ops | -0.51 | -0.82 | -0.87 | -0.54 | -0.68 |
| EPS Basic Continuous Ops | -0.51 | -0.82 | -0.87 | -0.54 | -0.68 |
| EPS Diluted Total Ops | -0.51 | -0.82 | -0.87 | -0.54 | -0.68 |
| EPS Diluted Continuous Ops | -0.51 | -0.82 | -0.87 | -0.54 | -0.68 |
| EPS Diluted Before Non-Recurring Items | -0.55 | -0.91 | -0.97 | N/A | N/A |
| EBITDA(a) | $-18,551 | $-26,067 | $-25,800 | $-14,831 | $-13,272 |